Bookmark and Share

Andrei  Maiseyeu

Andrei Maiseyeu Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Medicine
Location: HSF2 Rm 012D

Personal History:

Professional Biography

I received both my M.S. (2002) and Ph.D. (2006) from the M.V. Lomonosov Moscow State University in Russia. I conducted postdoctoral research in cardiovascular nano- and bio-medicine at Ohio State's Dorothy M. Davis Heart and Lung Research Institute (DHLRI) and have served as an American Heart Association postdoctoral fellow at DHLRI. Previously, I was a Research Assistant Professor in the department of Internal Medicine at Ohio State University. I joined the faculty at the University of Maryland, Baltimore in December of 2013.

Research Interests:

I have over 15 years of research experience in organic chemistry. More recently, my focus has turned to medical imaging and cardiovascular disease.  Most of my research projects are interdisciplinary and highly collaborative.  I study environmental particles and their effects on cardiovascular health, develop novel nanoprobes and agents for targeted imaging and therapeutic delivery, investigate lipoproteins and their function, and engage in myriad interdepartmental/multi-institutional projects. Five current themes of my research:

Cardiovascular “Eat-Me” Imaging

My research team and I develop and test new nanoparticles agents, which are tiny devices engineered to target cardiovascular disease while avoiding healthy tissues and organs.  We engineer nanoparticle probes that selectively accumulate in atherosclerosis (the prerequisite condition of heart disease), making them avoid healthy organs and tissues, and diminishing dangerous side effects. Here, our science was inspired by an intrinsic, naturally occurred mechanism which deals with the removal of ‘unwanted’ cells by the organism. This entails targeting macrophages, the cells found in large numbers at the sites of atherosclerosis, by means of nanoprobes that display “eat-me” signals.  These “eat-me” signals are normally found on the surface of apoptotic (i.e., dying) cells, which are cleared rapidly by macrophages. When our nano-probes are injected, they get recognized by macrophages, engulfed, and are retained at sites of disease allowing their location through MRI.

Therapy and Diagnosis through “Theranostics”

Coupling magnetic resonance imaging with drug delivery is an attractive technology that merges therapy and diagnostic methods—what is often termed “theranostic.” We develop multifunctional nanoparticle agents equipped with ligands, imaging probes, and therapeutics. Ligands will aid our nanoparticles to the sites of disease, imaging probes will enable MRI detection, and therapeutics will allow for treatment. We make these nanoparticles accumulate in atherosclerosis, allowing to better locate and assess disease progression and response to therapy.

Escaping Clearance via Nanosystems

Many nanoparticles have been developed so far, but the major breakthrough is to be made by probes that avoid reticuloendothelial system (RES). A large percentage of injected doses of a typical agent will be cleared off (removed from circulation) by RES organs such as spleen, kidneys, and liver. A challenge faced by researchers is that many of imaging probes exhibit so-called ‘off-target’ (i.e., unintended) retention in normal organs. Our laboratory attempts to address some of the key issues with most drug delivery systems: lack of specificity, off-target effects, and poor imaging contrast of conventional contrast agents. We design  ‘clicking’ nanosystems, which are tiny, nanoscale devices equipped with unique mechanism allowing them to converge and accumulate only in sites of the disease.

Nanoscale Cholesterol Trafficking

Cholesterol transport plays a key role in mediating the development of cardiovascular disease and its progression. We develop synthetic nanoprobes that can obtain cholesterol flux information in vitro and in vivo through Förster Resonance Energy Transfer (FRET) spectroscopy. Our team is able to conduct real-time cholesterol release monitoring  in order to evaluate a patient’s high-density lipoprotein (HDL) function—an important metric in determining cardiovascular risk.

Aspects of HDL Function

Removing excess cholesterol from macrophages is thought to be one of the key mechanisms underlying atheroprotective properties of HDL. Our laboratory studies series of HDL function characteristics, such as such as oxidation status, ability to accept cholesterol (RCT), and anti-inflammatory properties. My team and I investigate HDL obtained from multiple patient populations participating in multiple interventions and environmental stressors (e.g., environmental pollutants and particulate matter). We also study HDL functionality in dysglycemic and diabetic patients, individuals engaging in in aerobic exercise, individuals exposed to particulate matter, and other situations.

Lab Techniques and Equipment:

Because my laboratory’s research focus is cardiovascular imaging, my team and I employ various diagnostic methods to detect cardiovascular disease and its biomarkers. We frequently use high-field magnetic resonance imaging, intravital confocal microscopy and whole-body fluorescence imaging. We conduct experiments, such as pharmacokinetic analysis and atherosclerosis biomarker identification and quantification. We also develop methods for isolation and purification via fast protein liquid chromatography (FPLC), ultracentrifugation, and flow-cytometric cell analysis. In our pharmacokinetic studies, HDL function investigations, and synthetic and natural nanoparticle work we use liquid chromatography-mass spectrometry (LCMS) in order to detect lipid biomarkers, small molecules, and peptides.



  1. Rajagopalan S, Badgeley MA, & Maiseyeu A (2013) Cholesterol Efflux Assay Probe Formulations, Methods of Making and Using.  (US Patent App. 13/861,832).
  2. Blazek A, Rutsky J, Osei K, Maiseyeu A, & Rajagopalan S (2013) Exercise-mediated changes in high-density lipoprotein: Impact on form and function. American heart journal 166(3):392-400.
  3. Yang F, Zhang X, Maiseyeu A, Mihai G, Yasmeen R, DiSilvestro D, Maurya SK, Periasamy M, Bergdall KV, Gregg D, Sen CK, Roy S, Lee LJ, Rajagopalan S, & Ziouzenkova O (2012) The prolonged survival of fibroblasts with forced lipid catabolism in visceral fat following encapsulation in alginate-poly-l-lysine. Biomaterials 33(22):5638-5649.
  4. Maiseyeu A, Badgeley MA, Kampfrath T, Mihai G, Deiuliis JA, Liu C, Sun Q, Parthasarathy S, Simon DI, Croce K, & Rajagopalan S (2012) In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arteriosclerosis, thrombosis, and vascular biology 32(4):962-970.
  5. Bandyopadhyay S, Xia X, Maiseiyeu A, Mihai G, Rajagopalan S, & Bong D (2012) Z-group ketone chain transfer agents for RAFT polymer nanoparticle modification via hydrazone conjugation. Macromolecules 45(17):6766-6773.
  6. Deiuliis JA, Kampfrath T, Ying Z, Maiseyeu A, & Rajagopalan S (2011) Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant mice. Lipids 46(11):1021-1032.
  7. Kampfrath T, Maiseyeu A, Ying Z, Shah Z, Deiuliis JA, Xu X, Kherada N, Brook RD, Reddy KM, Padture NP, Parthasarathy S, Chen LC, Moffatt-Bruce S, Sun Q, Morawietz H, & Rajagopalan S (2011) Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways. Circulation research 108(6):716-726.
  8. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, & Rajagopalan S (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124(21):2338-2349.
  9. Maiseyeu A, Mihai G, Roy S, Kherada N, Simonetti OP, Sen CK, Sun Q, Parthasarathy S, & Rajagopalan S (2010) Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: An approach for atherosclerosis imaging. Nanomedicine 5(9):1341-1356.
  10. Maiseyeu A, Mihai G, Kampfrath T, Simonetti OP, Sen CK, Roy S, Rajagopalan S, & Parthasarathy S (2009) Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. Journal of lipid research 50(11):2157-2163.